Collaboration Target Sample Clauses

Collaboration Target. In the event that, for a given Collaboration Target, there is any Collaboration Development Candidate for which Licensee delivers to Licensor an Option Declination Notice stating that Licensee reverts its rights relating to such Collaboration Target to Licensor, or such rights otherwise lapse and expire in accordance with Section 3.2(c)(iii)(B), then, in such case, all Options with respect to such Collaboration Target (including all related Collaboration Development Candidates) shall lapse and expire upon Licensor’s receipt of such Option Declination Notice or expiration pursuant to Section 3.2(c)(iii)(B) for such Collaboration Target and all rights to such Collaboration Target (including all related Collaboration Development Candidates) will revert to Licensor; provided, however, that such rights will not revert if the Option Declination Notice for such Collaboration Development Candidate states that Licensee retains its rights relating to such Collaboration Target, in which case, subject to the limitations on the obligations of Licensor as set forth in Section 2.5, Licensor will continue to Develop new Collaboration Development Candidates for such Collaboration Target, at Licensee’s expense, and Licensee shall retain exclusivity of such Collaboration Target. For the avoidance of doubt, regardless of the reversions of any rights pursuant to this Section 3.2(d)(i), Section 4.3 shall apply pursuant to its terms.

Collaboration Target. The term “Collaboration Target” shall mean each of the [***] biological targets (as described by a UniProt/SwissProt identifier) as of the Effective Date and as may be selected by Calico pursuant to Section 3.1.2(a) and/or Section 3.1.2(b), and shall include any splice variants, mutants, and natural variants reasonably associated with such UniProt number. Appendix 1.26 to this Agreement lists the Collaboration Targets. The initial Collaboration Targets are listed on Appendix 1.26, and the Parties shall update Appendix 1.26 during the term to add additional targets that are added as Collaboration Targets pursuant to Section 3.1.2(a) and/or Section 3.1.2(b).

Collaboration Target. If, with respect to a given Collaboration Target, there is any Collaboration Development Candidate for which Licensee provides notice to Licensor that Licensee decides not to continue to Develop and Commercialize following Option exercise and that Licensee reverts its rights relating to such Collaboration Target (including all related Collaboration Development Candidates) to Licensor, then all rights to such Collaboration Target (including all related Collaboration Development Candidates) will revert to Licensor along with any intellectual property developed by Licensee covering such Collaboration Development Candidates or any method of use or method of manufacture of such Collaboration Development Candidates; provided, however, that such rights will not revert if Licensee’s notice of its decision not to continue to Develop and Commercialize a Collaboration Development Candidate following Option exercise states that Licensee wishes to continue to Develop new Collaboration Development Candidates for such Collaboration Target, in which case, subject to the limitations on the obligations of Licensor as set forth in Section 2.5, Licensor will continue to THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. perform such Development, at Licensee’s expense, and Licensee shall retain exclusivity of such Collaboration Target.

Collaboration Target. Such exclusivity on a Collaboration Target will continue until the earlier of (i) the date such Collaboration Target is removed from the Collaboration in accordance with Section 1.5.2, 1.6.1 or 1.8; and (ii) the occurrence of an Option Deadline with respect to the applicable Collaboration Program and GSK does not exercise the Option for such Collaboration Program.

Collaboration Target. Section 1.27 of the Agreement is hereby deleted in its entirety and replaced with the following:

Collaboration Target. Subject to the exceptions in Section 3.9.4 (Exclusivity; Exceptions), from the Effective Date, ▇▇▇▇▇ shall not, either alone or with or through any Affiliate or Third Party: (a) until the termination or expiration of this Agreement with respect to the Collaboration Target in any country or other jurisdiction in the Territory, (i) Commercialize or Manufacture commercial supply of or (ii) license, authorize, appoint or otherwise enable any Third Party to Commercialize or Manufacture commercial supply of, in either case ((i) or (ii)), [**] the Collaboration Target; (b) until the termination or expiration of this Agreement with respect to the Collaboration Target in the United States, (i) Develop or Manufacture pre-clinical or clinical supply of or (ii) license, authorize, appoint or otherwise enable any Third Party to Develop or Manufacture pre-clinical or clinical supply of, in either case ((i) or (ii)), [**] the Collaboration Target; and (c) [**], in any country or other jurisdiction in the Territory outside of the United States, [**].